Truvestments Capital LLC Buys Shares of 1,700 The Chemours Company (NYSE:CC)

Truvestments Capital LLC acquired a new position in shares of The Chemours Company (NYSE:CC) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 1,700 shares of the specialty chemicals company’s stock, valued at approximately $35,000.

Other large investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in Chemours by 3.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 91,345 shares of the specialty chemicals company’s stock worth $2,399,000 after purchasing an additional 2,932 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Chemours in the 1st quarter valued at $1,764,000. New Covenant Trust Company N.A. acquired a new stake in shares of Chemours during the 1st quarter valued at $29,000. EMC Capital Management grew its position in Chemours by 26.5% during the 1st quarter. EMC Capital Management now owns 9,534 shares of the specialty chemicals company’s stock worth $250,000 after acquiring an additional 1,998 shares during the last quarter. Finally, Burney Co. increased its holdings in Chemours by 0.3% in the 1st quarter. Burney Co. now owns 197,046 shares of the specialty chemicals company’s stock worth $5,174,000 after purchasing an additional 601 shares in the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Alvenia Scarborough sold 7,500 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.47% of the stock is currently owned by company insiders.

Chemours Stock Performance

Shares of CC opened at $21.82 on Thursday. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The firm’s fifty day simple moving average is $19.53 and its two-hundred day simple moving average is $21.39. The Chemours Company has a 12 month low of $15.10 and a 12 month high of $32.70. The stock has a market capitalization of $3.26 billion, a P/E ratio of 42.96 and a beta of 1.75.

Chemours (NYSE:CC) last announced its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 EPS. As a group, analysts predict that The Chemours Company will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be paid a $0.25 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.00 annualized dividend and a dividend yield of 4.58%. Chemours’s dividend payout ratio is currently 200.00%.

Wall Street Analysts Forecast Growth

CC has been the topic of a number of recent research reports. Royal Bank of Canada cut their price target on Chemours from $28.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Barclays boosted their target price on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. BMO Capital Markets raised their price target on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, October 7th. The Goldman Sachs Group reduced their price objective on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. cut their target price on Chemours from $25.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Chemours presently has an average rating of “Hold” and a consensus price target of $24.88.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.